AI Health Tech vs. Real Cures AI health tech is booming, but the cures are not. The drug discovery revolution is real but radically overstated.
Health chatbots are a documented hazard, and diseases that matter most remain unsolved. At Novartis, in late 2025, researchers used AI to screen 15 million molecules a day for Huntington's disease treatment. From those 15 million candidates, only 60 were synthesized in the lab.
While an impressive feat of computational triage, it's not a cure. This gap between AI's laboratory potential and patient outcomes is the defining tension of health tech in 2026. The industry talks revolution; the evidence describes incremental, uncertain, and often disappointing progress.
While AI can compress drug discovery timelines by 30-40% and reduce preclinical development time, no AI-discovered drug has received FDA approval yet . Here's why: Traditional pharmaceutical failure rates stand at 90%, a figure AI hasn't fundamentally changed. AI-discovered compounds appear to show progression rates similar to traditionally discovered ones.
As of December 2025, at least 75 drugs or vaccines from AI-first biotechs had entered clinical trials , but the technology remains in its early stages.